Claret Medical said today that it secured up to $18 million in Series B financing it plans to use to make progress toward the U.S. market.
Claret said the new cash will help complete a U.S. pivotal trial of the Sentinel cerebral protection device, which filters potentially dangerous blood clots that may dislodge during valve replacement procedures. The device won investigational device exemption in February after winning CE Mark approval in the European Union a month earlier.
Help employers find you! Check out all the jobs and post your resume.
